Scilex Holding Company (SCLXW)
- Previous Close
0.2300 - Open
0.2101 - Bid --
- Ask --
- Day's Range
0.2100 - 0.2832 - 52 Week Range
0.2100 - 0.2832 - Volume
30,066 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 1.16
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company has a collaboration with ACEA Therapeutics to Support the Expansion of ZTlido program. Scilex Holding Company is headquartered in Palo Alto, California.
www.scilexholding.comRecent News: SCLXW
View MoreCompare To: SCLXW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SCLXW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-233.88%
Return on Assets (ttm)
-53.64%
Return on Equity (ttm)
--
Revenue (ttm)
50.83M
Net Income Avi to Common (ttm)
-171.53M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
6.89M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
57.29M
Company Insights: SCLXW
SCLXW does not have Company Insights